Akoya Biosciences Dirección

Dirección controles de criterios 2/4

Akoya Biosciences' El consejero delegado es Brian McKelligon , nombrado en Jul 2017, tiene un mandato de 6.42 años. la remuneración anual total es $3.05M , compuesta por 17% salario y 83% primas, incluidas acciones y opciones de la empresa. posee directamente 0.026% de las acciones de la empresa, por valor de $54.78K . La antigüedad media del equipo directivo y del consejo de administración es de 4.6 años y 6.4 años respectivamente.

Información clave

Brian McKelligon

Chief Executive Officer (CEO)

US$3.0m

Compensación total

Porcentaje del salario del CEO	17.0%
Permanencia del CEO	6.8yrs
Participación del CEO	0.08%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	3.7yrs

Actualizaciones recientes de la dirección

Recent updates

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Feb 28

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Nov 25

Akoya Biosciences Seeks Growth Despite Higher Operating Losses

May 30

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11

Akoya Biosciences and AstraZeneca ink collaboration agreement

Jun 04

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Brian McKelligon en comparación con los beneficios de Akoya Biosciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$63m
Sep 30 2023	n/a	n/a	-US$71m
Jun 30 2023	n/a	n/a	-US$76m
Mar 31 2023	n/a	n/a	-US$73m
Dec 31 2022	US$3m	US$518k	-US$71m
Sep 30 2022	n/a	n/a	-US$69m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$51m
Dec 31 2021	US$2m	US$393k	-US$44m
Sep 30 2021	n/a	n/a	-US$34m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$28m
Dec 31 2020	US$516k	US$350k	-US$22m
Dec 31 2019	US$484k	US$333k	-US$18m

Compensación vs. Mercado: Brian($USD3.05M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD1.53M).

Compensación vs. Ingresos: La compensación de Brian ha aumentado mientras la empresa no es rentable.

CEO

Brian McKelligon (54 yo)

6.8yrs

Permanencia

US$3,049,639

Compensación

Mr. Brian McKelligon has been Chief Executive Officer and Director at Akoya Biosciences, Inc. since July 2017 and also serves as its President. Prior to joining Akoya, he led corporate and business develop...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Brian McKelligon	President	6.8yrs	US$3.05m	0.076% $ 143.4k
John Ek	CFO, Principal Financial Officer & Principal Accounting Officer	1.1yrs	sin datos	0.093% $ 176.1k
Frederic Pla	Chief Operating Officer	3.1yrs	US$3.33m	0.062% $ 116.5k
Priyam Shah	Senior Director of Business Development & Investor Relations Strategy	no data	sin datos	sin datos
Jennifer Kamocsay	General Counsel	1.2yrs	sin datos	0.012% $ 23.5k
Niro Ramachandran	Chief Business Officer	3.7yrs	US$365.22k	0.29% $ 557.5k
Pascal Bamford	Senior Vice President	2.5yrs	sin datos	sin datos
Rob Hart	Secretary	no data	sin datos	sin datos

2.8yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: AKYAEl equipo directivo de la empresa se considera experimentado (4.6 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Brian McKelligon	President	6.8yrs	US$3.05m	0.076% $ 143.4k
Robert Shepler	Chairman of the Board	8.4yrs	US$251.25k	0.75% $ 1.4m
Myla Lai-Goldman	Independent Director	2.6yrs	US$230.62k	0.041% $ 77.0k
Thomas Schnettler	Independent Director	4.6yrs	US$222.50k	sin datos
Thomas Raffin	Director	8.4yrs	US$213.75k	0.48% $ 903.2k
Matthew Winkler	Independent Director	6.8yrs	US$231.25k	2% $ 3.8m
James Allison	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Scott Mendel	Independent Director	2.8yrs	US$246.87k	0.058% $ 109.7k
Padmanee Sharma	Member of Scientific Advisory Board	less than a year	sin datos	sin datos
Garry Nolan	Chair of the Scientific Advisory Board	less than a year	US$218.75k	1.26% $ 2.4m

3.7yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de AKYA se considera experimentada (6.4 años de antigüedad promedio).

Akoya Biosciences Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

High number of new directors

Chief Operating Officer recently bought US$92k worth of stock

Akoya Biosciences, Inc. Announces Executive Changes

Chief Financial Officer exercised options to buy US$2.2m worth of stock.

Chief Financial Officer exercised options and sold US$298k worth of stock

President exercised options and sold US$59k worth of stock

Recent updates

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale

Consensus EPS estimates upgraded to US$0.83 loss

Full year 2023 earnings: EPS exceeds analyst expectations

Is Akoya Biosciences (NASDAQ:AKYA) Weighed On By Its Debt Load?

Akoya Biosciences, Inc. to Report Q4, 2023 Results on Mar 04, 2024

High number of new directors

Akoya Biosciences Deploys the Maxfuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory At Stanford University for Multiomic Integration of Spatial and Single-Cell Data on the Enable Medicine Platform

Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 and for the Fiscal Year 2024

Price target decreased by 11% to US$9.25

Investors Still Aren't Entirely Convinced By Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Revenues Despite 31% Price Jump

Consensus EPS estimates upgraded to US$1.46 loss

New minor risk - Share price stability

Price target decreased by 8.3% to US$11.00

Akoya Biosciences, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023

Price target decreased by 7.1% to US$13.13

Akoya Biosciences, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Akoya Biosciences, Inc. Launches PhenoCycler-Fusion 2.0 and Phenoimager HT 2.0 Platform Upgrades

Chief Operating Officer recently bought US$92k worth of stock

Akoya Biosciences, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Price target decreased by 12% to US$14.14

Akoya Biosciences, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Price target decreased by 8.6% to US$16.00

New minor risk - Share price stability

Akoya Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $43.5 million.

Akoya Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $43.5 million.

Akoya Biosciences, Inc. Announces Executive Changes

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2023

Price target decreased by 7.9% to US$17.50

Consensus EPS estimates fall by 11%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Akoya Biosciences, Inc. to Report Q4, 2022 Results on Mar 06, 2023

Akoya Biosciences, Inc. to Present First-of-its-Kind Spatial Multiomics Dataset at 2023 AGBT General Meeting

Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Fiscal Year 2022

Chief Financial Officer exercised options to buy US$2.2m worth of stock.

Chief Financial Officer exercised options and sold US$298k worth of stock

President exercised options and sold US$59k worth of stock

Co-Founder recently sold US$67k worth of stock

Co-Founder notifies of intention to sell stock

Co-Founder recently sold US$325k worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Akoya Biosciences, Inc Launches PhenoCode Signature Panels to Accelerate Development of Predictive Biomarkers for Cancer Immunotherapy

Akoya Biosciences, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Co-Founder recently sold US$319k worth of stock

President exercised options and sold US$63k worth of stock

Price target increased to US$20.40

Consensus forecasts updated

Akoya Biosciences, Inc. Raises Earnings Guidance for the Full Year 2022

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Akoya Biosciences, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Price target decreased to US$18.60

President notifies of intention to sell stock

Akoya Biosciences Seeks Growth Despite Higher Operating Losses

Consensus forecasts updated

Akoya Biosciences, Inc. (NASDAQ:AKYA) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Akoya Biosciences, Inc. Revises Revenue Guidance for the Full Year of 2022

Price target decreased to US$20.50

Akoya Biosciences, Inc., Annual General Meeting, Jun 01, 2022

Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer

Chief Business Officer exercised options to buy US$844k worth of stock.

Akoya Biosciences, Inc. to Report Q1, 2022 Results on May 05, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS misses analyst expectations

Akoya Biosciences, Inc. to Report Q4, 2021 Results on Mar 14, 2022

Akoya Biosciences Announces Commercial Launch of PhenoCycler-Fusion, the Faster Single-Cell Spatial Biology System

Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2021